Advertisement

Topics

'Promising Option' for IOP Reduction

06:33 EDT 14 Jun 2018 | Medscape

A review of the study that led to the recent approval of latanoprostene bunod for open-angle glaucoma and ocular hypertension.
Medscape Ophthalmology

Original Article: 'Promising Option' for IOP Reduction

NEXT ARTICLE

More From BioPortfolio on "'Promising Option' for IOP Reduction"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of affected individuals. Symptoms can range from mild breathles...